ASCO Annual Meeting - Chicago, IL, May 29 –June 2, 2015; Abstract - Interleukin 2 - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-12-11 00:15:33 Immune system Immunology T cells Cancer treatments Programmed cell death protein 1 Regulatory T cell Interferon gamma Immunotherapy LAG3 Immune checkpoint CD4+ T cells and antitumor immunity Interleukin 21		ASCO Annual Meeting - Chicago, IL, May 29 –June 2, 2015; Abstract #3017 Poster #: 343 A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. Jeffrey R. Infante1, Add to Reading List Source URL: www.armobio.com Download Document from Source Website File Size: 1,59 MB Share Document on Facebook

	Evaluation of Interferon-gamma-Producing T Cells DocID: 1uFKZ - View Document
	  Data Sheet Recombinant Human Interferon-gamma (rh IFN-) Preclinical Grade - Order No.: µg) DocID: 1u1rK - View Document
	PEGylated IL-10 (AM0010) for advanced solid tumors - a Phase 1 study Jeffrey R. Infante1, Aung Naing2, Kyriakos P. Papadopoulos3, Karen A. Autio4, Patrick A. Ott5, Deborah J. Wong6, Gerald S. Falchook7, Manish Patel1,8 , DocID: 1r5tc - View Document
	Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with Pancreatic or Colorectal Cancer. Kyriakos P. Papadopoulos1, Aung Naing2, Jeffrey R. Infante3*, Deborah J. Wong6, Karen A. Autio4, Patrick A. Ott5, DocID: 1qBPZ - View Document
	BELONGINGNESS Transcript origin analysis identifies antigenpresenting cells as primary targets DocID: 1qatN - View Document